A European Institute for Biomedical Imaging Research (EIBIR)/European Network for Cell Imaging and Tracking Expertise (ENCITE) educational workshop, called “Cells at work: Imaging in health and disease,” will take place May 18-19 at the University of Mons in Belgium.
A European Institute for Biomedical Imaging Research (EIBIR)/European Network for Cell Imaging and Tracking Expertise (ENCITE) educational workshop, called “Cells at work: Imaging in health and disease,” will take place May 18-19 at the University of Mons in Belgium.
ENCITE is a collaborative project coordinated by EIBIR. It is related to the theme “Cooperation health: in vivo image-guidance for cell therapy,” and is supported by the European Commission within the 7th Framework Programme for Research. It started in June 2009, thanks to a financial contribution of €12 million. ENCITE is a four-year project and has 29 project partners from 11 countries with expertise in the field of cell imaging.
The mission of the project is to develop and test new MR and optical imaging methods and biomarkers to get a more comprehensive picture of cell fate and reactions of the immune system, and ultimately to improve and further develop cell therapy for the benefit of the European patient. Details on the interim results can be found here.
The deadline to register is April 20.
For more information, please contact: office@eibir.org.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.